Chang Chen, Zhang Bin, Chen Jingli, Wang Guorong
Department of Pathology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China.
FirstDepartment of General Surgery, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China.
Front Oncol. 2025 Aug 27;15:1612143. doi: 10.3389/fonc.2025.1612143. eCollection 2025.
This study aimed to identify key genes associated with perineural invasion (PNI) in stage II colorectal cancer (CRC) and develop a prognostic nomogram. The goal was to create a model for more precise prognosis assessment and to guide personalized treatment for stage II CRC patients with PNI.
Bioinformatic analysis of The Cancer Genome Atlas (TCGA) database was used to identify differentially expressed genes (DEGs) associated with PNI in stage II CRC. Kaplan-Meier and Cox regression analyses identified prognostic genes for overall survival (OS). These genes, along with clinical factors, were integrated into a nomogram. The model's performance was evaluated using calibration curves, receiver operating characteristic (ROC)/area under the curve (AUC) analysis, and decision curve analysis (DCA). Key gene expression in CRC tissues was validated by immunohistochemistry (IHC) and correlated with clinicopathological parameters.
We identified 33 DEGs associated with stage II CRC and PNI. High expression of CLDN18 and FTCD were independent poor prognostic indicators. A nomogram incorporating these genes and clinical factors accurately predicted 1-, 3-, and 5-year overall survival (OS), with AUC values exceeding 0.7. Calibration curves and DCA confirmed the model's clinical utility. Immunohistochemistry (IHC) revealed that Claudin 18 protein expression was significantly higher in PNI-positive CRC tissues (P < 0.05) and correlated with age and lymphatic invasion (P < 0.05).
We developed a novel prognostic nomogram for stage II CRC patients with PNI. This model provides a new tool for CRC prognosis, deepens the understanding of PNI pathogenesis, and helps identify therapeutic targets like Claudin 18, whose expression was confirmed as a potential biomarker. This tool can enhance personalized treatment strategies for this high-risk patient population.
本研究旨在识别与Ⅱ期结直肠癌(CRC)神经周围侵犯(PNI)相关的关键基因,并构建一个预后列线图。目标是创建一个用于更精确预后评估的模型,以指导Ⅱ期伴有PNI的CRC患者的个性化治疗。
利用癌症基因组图谱(TCGA)数据库进行生物信息学分析,以识别与Ⅱ期CRC中PNI相关的差异表达基因(DEG)。通过Kaplan-Meier和Cox回归分析确定总生存(OS)的预后基因。将这些基因与临床因素整合到一个列线图中。使用校准曲线、受试者工作特征(ROC)/曲线下面积(AUC)分析和决策曲线分析(DCA)评估该模型的性能。通过免疫组织化学(IHC)验证CRC组织中的关键基因表达,并将其与临床病理参数相关联。
我们识别出33个与Ⅱ期CRC和PNI相关的DEG。CLDN18和FTCD的高表达是独立的不良预后指标。一个纳入这些基因和临床因素的列线图准确预测了1年、3年和5年总生存(OS),AUC值超过0.7。校准曲线和DCA证实了该模型的临床实用性。免疫组织化学(IHC)显示,Claudin 18蛋白表达在PNI阳性的CRC组织中显著更高(P < 0.05),并与年龄和淋巴侵犯相关(P < 0.05)。
我们为伴有PNI的Ⅱ期CRC患者开发了一种新的预后列线图。该模型为CRC预后提供了一种新工具,加深了对PNI发病机制的理解,并有助于识别像Claudin 18这样的治疗靶点,其表达被确认为一种潜在的生物标志物。该工具可以加强针对这一高危患者群体的个性化治疗策略。